{"transactions":[{"id":718648,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":33045,"kind":"person","name":"Sloan Sheldon","position":1,"cik":"0002038798","reported_name":"Sloan Sheldon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-03T01:33:02.000Z","date":"2026-07-01","kind":"exercise","planned":true,"acquired":false,"shares":8334,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option represents the right to purchase 400,000 shares of the Issuer's common stock, one quarter of which vested and became exercisable on October 1, 2025, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer."}],"balance_after":305000,"derivative":{"exercise_price":27.46,"expiration_date":"2034-10-01","underlying":"Common Stock","underlying_shares":8334},"source":{"system":"sec-edgar","filing":"0001636282-26-000087","document":"wk-form4_1783042377.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2038798/000163628226000087/wk-form4_1783042377.xml","form_type":"4"}},{"id":718647,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":33045,"kind":"person","name":"Sloan Sheldon","position":1,"cik":"0002038798","reported_name":"Sloan Sheldon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-07-03T01:33:02.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":1834,"price":88.34,"value":162015.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.03 to $88.95, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001636282-26-000087","document":"wk-form4_1783042377.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2038798/000163628226000087/wk-form4_1783042377.xml","form_type":"4"}},{"id":718646,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":33045,"kind":"person","name":"Sloan Sheldon","position":1,"cik":"0002038798","reported_name":"Sloan Sheldon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-07-03T01:33:02.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":6500,"price":87.52,"value":568880.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $87.03 to $87.99, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price\nwithin the range."}],"balance_after":1834,"source":{"system":"sec-edgar","filing":"0001636282-26-000087","document":"wk-form4_1783042377.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2038798/000163628226000087/wk-form4_1783042377.xml","form_type":"4"}},{"id":718645,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":33045,"kind":"person","name":"Sloan Sheldon","position":1,"cik":"0002038798","reported_name":"Sloan Sheldon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-07-03T01:33:02.000Z","date":"2026-07-01","kind":"exercise","planned":true,"acquired":true,"shares":8334,"price":27.46,"value":228851.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."}],"balance_after":8334,"source":{"system":"sec-edgar","filing":"0001636282-26-000087","document":"wk-form4_1783042377.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2038798/000163628226000087/wk-form4_1783042377.xml","form_type":"4"}},{"id":752329,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":33045,"kind":"person","name":"Sloan Sheldon","position":1,"cik":"0002038798","reported_name":"Sloan Sheldon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-04T01:32:02.000Z","date":"2026-06-03","kind":"exercise","planned":true,"acquired":false,"shares":8333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option represents the right to purchase 400,000 shares of the Issuer's common stock, one quarter of which vested and became exercisable on October 1, 2025, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer."}],"balance_after":313334,"derivative":{"exercise_price":27.46,"expiration_date":"2034-10-01","underlying":"Common Stock","underlying_shares":8333},"source":{"system":"sec-edgar","filing":"0001636282-26-000078","document":"wk-form4_1780536719.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2038798/000163628226000078/wk-form4_1780536719.xml","form_type":"4"}},{"id":752328,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":33045,"kind":"person","name":"Sloan Sheldon","position":1,"cik":"0002038798","reported_name":"Sloan Sheldon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-06-04T01:32:02.000Z","date":"2026-06-03","kind":"sale","planned":true,"acquired":false,"shares":8333,"price":75,"value":624975.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001636282-26-000078","document":"wk-form4_1780536719.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2038798/000163628226000078/wk-form4_1780536719.xml","form_type":"4"}},{"id":752327,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":33045,"kind":"person","name":"Sloan Sheldon","position":1,"cik":"0002038798","reported_name":"Sloan Sheldon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-06-04T01:32:02.000Z","date":"2026-06-03","kind":"exercise","planned":true,"acquired":true,"shares":8333,"price":27.46,"value":228824.18,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."}],"balance_after":8333,"source":{"system":"sec-edgar","filing":"0001636282-26-000078","document":"wk-form4_1780536719.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2038798/000163628226000078/wk-form4_1780536719.xml","form_type":"4"}},{"id":795921,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":33045,"kind":"person","name":"Sloan Sheldon","position":1,"cik":"0002038798","reported_name":"Sloan Sheldon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-02T01:34:39.000Z","date":"2026-05-01","kind":"exercise","planned":true,"acquired":false,"shares":78333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"This option represents the right to purchase 400,000 shares of the Issuer's common stock, one quarter of vested and became exercisable on October 1, 2025, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer."}],"balance_after":321667,"derivative":{"exercise_price":27.46,"expiration_date":"2034-10-01","underlying":"Common Stock","underlying_shares":78333},"source":{"system":"sec-edgar","filing":"0002038798-26-000004","document":"wk-form4_1777685676.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/2038798/000203879826000004/wk-form4_1777685676.xml","form_type":"4"}},{"id":795920,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":33045,"kind":"person","name":"Sloan Sheldon","position":1,"cik":"0002038798","reported_name":"Sloan Sheldon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-05-02T01:34:39.000Z","date":"2026-05-01","kind":"sale","planned":true,"acquired":false,"shares":400,"price":75.37,"value":30148.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0002038798-26-000004","document":"wk-form4_1777685676.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/2038798/000203879826000004/wk-form4_1777685676.xml","form_type":"4"}},{"id":795919,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":33045,"kind":"person","name":"Sloan Sheldon","position":1,"cik":"0002038798","reported_name":"Sloan Sheldon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-05-02T01:34:39.000Z","date":"2026-05-01","kind":"sale","planned":true,"acquired":false,"shares":5059,"price":74.6,"value":377401.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $74.21 to $74.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":400,"source":{"system":"sec-edgar","filing":"0002038798-26-000004","document":"wk-form4_1777685676.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/2038798/000203879826000004/wk-form4_1777685676.xml","form_type":"4"}},{"id":795918,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":33045,"kind":"person","name":"Sloan Sheldon","position":1,"cik":"0002038798","reported_name":"Sloan Sheldon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-05-02T01:34:39.000Z","date":"2026-05-01","kind":"sale","planned":true,"acquired":false,"shares":10358,"price":73.74,"value":763798.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $73.21 to $74.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":5459,"source":{"system":"sec-edgar","filing":"0002038798-26-000004","document":"wk-form4_1777685676.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/2038798/000203879826000004/wk-form4_1777685676.xml","form_type":"4"}},{"id":795917,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":33045,"kind":"person","name":"Sloan Sheldon","position":1,"cik":"0002038798","reported_name":"Sloan Sheldon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-05-02T01:34:39.000Z","date":"2026-05-01","kind":"sale","planned":true,"acquired":false,"shares":12777,"price":72.94,"value":931954.38,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $72.21 to $73.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":15817,"source":{"system":"sec-edgar","filing":"0002038798-26-000004","document":"wk-form4_1777685676.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2038798/000203879826000004/wk-form4_1777685676.xml","form_type":"4"}},{"id":795916,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":33045,"kind":"person","name":"Sloan Sheldon","position":1,"cik":"0002038798","reported_name":"Sloan Sheldon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-05-02T01:34:39.000Z","date":"2026-05-01","kind":"sale","planned":true,"acquired":false,"shares":8777,"price":71.56,"value":628082.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $71.21 to $72.19, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":28594,"source":{"system":"sec-edgar","filing":"0002038798-26-000004","document":"wk-form4_1777685676.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2038798/000203879826000004/wk-form4_1777685676.xml","form_type":"4"}},{"id":795915,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":33045,"kind":"person","name":"Sloan Sheldon","position":1,"cik":"0002038798","reported_name":"Sloan Sheldon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-05-02T01:34:39.000Z","date":"2026-05-01","kind":"sale","planned":true,"acquired":false,"shares":19656,"price":70.61,"value":1387910.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $70.21 to $71.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":37371,"source":{"system":"sec-edgar","filing":"0002038798-26-000004","document":"wk-form4_1777685676.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2038798/000203879826000004/wk-form4_1777685676.xml","form_type":"4"}},{"id":795914,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":33045,"kind":"person","name":"Sloan Sheldon","position":1,"cik":"0002038798","reported_name":"Sloan Sheldon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-05-02T01:34:39.000Z","date":"2026-05-01","kind":"sale","planned":true,"acquired":false,"shares":21306,"price":69.53,"value":1481406.18,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $69.21 to $70.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":57027,"source":{"system":"sec-edgar","filing":"0002038798-26-000004","document":"wk-form4_1777685676.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2038798/000203879826000004/wk-form4_1777685676.xml","form_type":"4"}},{"id":795913,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":33045,"kind":"person","name":"Sloan Sheldon","position":1,"cik":"0002038798","reported_name":"Sloan Sheldon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-05-02T01:34:39.000Z","date":"2026-05-01","kind":"exercise","planned":true,"acquired":true,"shares":78333,"price":27.46,"value":2151024.18,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."}],"balance_after":78333,"source":{"system":"sec-edgar","filing":"0002038798-26-000004","document":"wk-form4_1777685676.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2038798/000203879826000004/wk-form4_1777685676.xml","form_type":"4"}},{"id":817134,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":33045,"kind":"person","name":"Sloan Sheldon","position":1,"cik":"0002038798","reported_name":"Sloan Sheldon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-04T01:30:11.000Z","date":"2026-04-01","kind":"exercise","planned":true,"acquired":false,"shares":7958,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option represents a right to purchase 95,500 shares of the Issuer's common stock, which will vest in equal monthly installments over four years, subject to the Reporting Person's continued employment with the Issuer at each vesting date."}],"balance_after":87542,"derivative":{"exercise_price":21.66,"expiration_date":"2035-01-15","underlying":"Common Stock","underlying_shares":7958},"source":{"system":"sec-edgar","filing":"0001636282-26-000030","document":"wk-form4_1775266209.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2038798/000163628226000030/wk-form4_1775266209.xml","form_type":"4"}},{"id":817133,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":33045,"kind":"person","name":"Sloan Sheldon","position":1,"cik":"0002038798","reported_name":"Sloan Sheldon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-04-04T01:30:11.000Z","date":"2026-04-01","kind":"sale","planned":true,"acquired":false,"shares":7958,"price":50,"value":397900.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001636282-26-000030","document":"wk-form4_1775266209.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2038798/000163628226000030/wk-form4_1775266209.xml","form_type":"4"}},{"id":817132,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":33045,"kind":"person","name":"Sloan Sheldon","position":1,"cik":"0002038798","reported_name":"Sloan Sheldon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-04-04T01:30:11.000Z","date":"2026-04-01","kind":"exercise","planned":true,"acquired":true,"shares":7958,"price":21.66,"value":172370.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."}],"balance_after":7958,"source":{"system":"sec-edgar","filing":"0001636282-26-000030","document":"wk-form4_1775266209.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2038798/000163628226000030/wk-form4_1775266209.xml","form_type":"4"}},{"id":940195,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":33045,"kind":"person","name":"Sloan Sheldon","position":1,"cik":"0002038798","reported_name":"Sloan Sheldon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-14T02:26:35.000Z","date":"2026-01-09","kind":"grant","planned":false,"acquired":true,"shares":140000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase 140,000 shares of the Issuer's common stock, which will vest in equal monthly installments over four years, subject to the Reporting Person's continued employment with the Issuer at each vesting date."}],"balance_after":140000,"derivative":{"exercise_price":30.61,"expiration_date":"2036-01-09","underlying":"Common Stock","underlying_shares":140000},"source":{"system":"sec-edgar","filing":"0001636282-26-000002","document":"wk-form4_1768357592.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2038798/000163628226000002/wk-form4_1768357592.xml","form_type":"4"}},{"id":1300413,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":33045,"kind":"person","name":"Sloan Sheldon","position":1,"cik":"0002038798","reported_name":"Sloan Sheldon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-17T21:36:00.000Z","date":"2025-01-15","kind":"grant","planned":false,"acquired":true,"shares":95500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase 95,500 shares of the Issuer's common stock, which will vest in equal monthly installments over four years, subject to the Reporting Person's continued employment with the Issuer at each vesting date."}],"balance_after":95500,"derivative":{"exercise_price":21.66,"expiration_date":"2035-01-15","underlying":"Common Stock","underlying_shares":95500},"source":{"system":"sec-edgar","filing":"0001636282-25-000009","document":"wk-form4_1737149753.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2038798/000163628225000009/wk-form4_1737149753.xml","form_type":"4"}},{"id":1396974,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":33045,"kind":"person","name":"Sloan Sheldon","position":1,"cik":"0002038798","reported_name":"Sloan Sheldon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-01T22:34:26.000Z","date":"2024-10-01","kind":"grant","planned":false,"acquired":true,"shares":400000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents the right to purchase 400,000 shares of the Issuer's common stock, one quarter of which will vest and become exercisable on October 1, 2025, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer."}],"balance_after":400000,"derivative":{"exercise_price":27.46,"expiration_date":"2034-10-01","underlying":"Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0001636282-24-000068","document":"wk-form4_1727822060.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2038798/000163628224000068/wk-form4_1727822060.xml","form_type":"4"}}]}